triplet combination therapy improves survival in mHSPC compared with doublet regimens. Our findings need to be confirmed in further head-to-head trials with longer follow-up sciencedirect.com/science/articl…

Yapılması planlanan ve bazı kurumlarca desteklenen, nefret temelli “LGBTİ+ karşıtı” yürüyüş çağrılarını kaygıyla izliyoruz. İlgili tüm kurum ve kişileri bu hatadan bir an önce dönmeye, hakikatin yanında durmaya ve sağduyuya çağırıyoruz.

Is it time for neoadjuvant before radical prostatectomy? 💊💉ARNEO: Degarelix with/Without Apalutamide Prior to RP for High-risk #ProstateCancer 🔶Minimal residual disease:DA 38%🆚D 9.1%, no pCR 🔶PTEN loss lesses MRD 11%🆚43% 🔶PROTEUS trial awaited OncoAlert European Association of Urology (EAU) ASCO

Dear #MedTwitter RCC therapy is becoming increasingly complex. Here an overview for you from the 5 pivotal trials. Hopefully it is useful for you for your presentations and clinical decision findings. Toni Choueiri, MD Sumanta K. Pal, MD, FASCO Santhosh Ambika Oncology Brothers OncoAlert Yüksel Ürün

#Twittorial on our recent @IBCG on risk stratifying intermediate risk NMIBC now in print in European Urology Oncology #bladdercancer #MedTwitter #UroSoMe doi.org/10.1016/j.euo.…

Assistant professor vs Editor

The rationale for removing the cancer designation from Gleason pattern 3 is 100% practical. What will happen if we continue to call pattern 3 cancer & what will happen if, instead, we use a label other than cancer? doi.org/10.1016/j.euru… Scott Eggener Matt Cooperberg

Medical prediction models typically have binary endpoint & give risk of cancer/death/MI etc. Any examples of prediction models with continuous endpoint? eg.amount pain relief from surgery. Frank Harrell mk Ben Van Calster Ewout Steyerberg Maarten van Smeden Gary Collins

New Platinum Priority Editorial from Andrew Vickers Matt Cooperberg Scott Eggener Removing the Designation of Cancer from Grade Group 1 Disease Will Do More Good than Harm buff.ly/3sjtbld

November 6 🎂🥳🎉: Happy birthday and long life to Alexandra Elbakyan! Neuroscientist and software developer #Alexandra Elbakyan who revolutionized the academic and scientific world with her ideals of open access to scientific knowledge.

If you remain interested in the G6/GG1 'cancer vs no cancer' discussion, should be aware of this paper by mostly pathologists but also plenty of clinicians. My/our response to their points in a thread to follow pubmed.ncbi.nlm.nih.gov/36083240/

Incorporating PSMA PET in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer buff.ly/3Avo0mE Laura Bukavina Amy Luckenbaugh Michael Hofman Sophia Kamran, MD Declan Murphy Kosj Yamoah MD, PhD Piet Ost

PSMA is here, it's time to learn how to use it most effectively in the diagnosis and treatment of our patients! Nature Reviews Urology OncoAlert Advanced Prostate Cancer Consensus Conference PCF Science RSNA SNMMI Piet Ost Shankar Siva Michael Hofman Declan Murphy prof. Stefano Fanti European Association of Urology (EAU) nature.com/articles/s4158…

We have more and strong options than ADT in the treatment of mCSPC. A living meta-analysis just published JAMA Oncology jamanetwork.com/journals/jamao… Yüksel Ürün silke gillessen Advanced Prostate Cancer Consensus Conference PCF Science OncoAlert

The surveillance rate for low-risk #ProstateCancer has risen from 27% to 60%, 2014-2021, but overtreatment remains common, with substantial local variation. Matt Cooperberg @dannymak #pcsm @amerurological Quality AQUA Registry ja.ma/3KOAMCM

Presented at #EAU23: In men with prostate cancer on PSA screening, radical treatments led to half the incidence of metastasis and local progression as active monitoring without affecting disease-specific or overall survival (ProtecT trial) nej.md/3Yvyn2V #oncology

2017'de hayatımız değişmişti. Değişmek durumunda kalmıştı. Elimizde bir a4 kağıdı karşımızda bulutların üstüne kadar yükselmiş aşılmaz sıradağlar vardı. Yolun adı otizm. Sıra dağların adları, eğiticilerin eğitimsizliği, farkındalık yoksunluğu, iletişim kuramayan öğretmenler vb.

Our collaborative review on LND in GU cancers; tremendous effort by Amanda Myers MD Anderson Cancer Center #OncSurgery European Urology Oncology Open Access link: authors.elsevier.com/a/1i6Q09Cfv-xp… Alberto Briganti B.C. Leibovich MD #SethLerner Marco Moschini Morgan Roupret Shahrokh F. Shariat Philippe spiess @Astenzl

Finally it’s online in World Journal of Urology. Meta-analysis #AEEP vs #TURP long-term outcomes. trebuchet.public.springernature.app/get_content/1b… Naturally, all benefits go for #AEEP. Thanks for all the experts who were involved Andrey Morozov Jeremy Teoh Juan Gómez Rivas Lukas Lusuardi Anastasia Shpikina Thomas RW Herrmann

En bloc TURBT (for <1 cm tumors) results in Similar recurrence rates: 18.4% vs 16.7% at 1 yr Similar residual disease on reTUR 56% vs 55.9% (small subset) More retrieval of DM: 80.7% vs 71.1% Less bladder perforation: 5.6% vs 12% Similar OR time: 26 vs 25 min